Diadexus Inc. (fka DDXSQ)

[Renee]

DDXSQ registration revoked:

https://www.sec.gov/litigation/opinions/2020/34-90586.pdf

[lucky, mydog]

https://www.sec.gov/litigation/opinions/2020/34-89599.pdf

[Renee]

DDXSQ SEC Suspension for severely delinquent Financials:

https://www.sec.gov/litigation/suspensions/2019/34-86759.pdf

Order:

https://www.sec.gov/litigation/suspensions/2019/34-86759-o.pdf

Admin. Proceeding:

https://www.sec.gov/litigation/admin/2019/34-86758.pdf

[TheFinalCD]

and trap

[ThirdSyte]

What a gap!!!!

[harley3296]

Garbage

[TheFinalCD]

.031x.08

what a spread~!

DDXSQ

[starkd748]

Lol nope

[Renee]

DDXS changed to DDXSQ, bankruptcy:

http://otce.finra.org/DLSymbolNameChanges

[willlbone]

Going to bounce 100%.
From 1 cent to 2 cent.

[Hawkeye_tt]

Could nor sell? Business Partner from May not interested.?
Thoughts on Why ?

Hawk

[willlbone]

Chap 11. Shares will be cancelled.

[subslover]

Diadexus, Inc. Previews First Quarter 2016 Financial Performance and Provides Business Update

SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 18, 2016) - Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced preliminary financial performance metrics for the first quarter ended March 31, 2016 and provided an update on its business.

"Our team's performance in executing our strategy to broaden and diversify our customer base as we launch our new PLAC® Activity Test is beginning to generate results and momentum in our business. During the first quarter, we have continued to contract with new customers as we launch our PLAC® Activity Test and we already are seeing volume growth as we deliver supply into regional and hospital labs, build awareness of the test's clinical utility and value, and drive demand for the product," said Lori Rafield, Ph.D., Chairman and Chief Executive Officer for Diadexus. "There is significant interest in this test from national labs, major hospital systems, regional reference labs, clinics and physician office labs as healthcare providers want FDA-cleared tests supported by extensive clinical data to inform decisions on how aggressively to manage patients who are at risk for coronary heart disease. Our commercial team has and will continue to execute on our strategy to broaden and diversify our base of customers and expect to deliver accelerating revenue growth through the launch of our PLAC® Activity Test."

Preliminary total revenues, comprised entirely of product sales, for the quarter ended March 31, 2016 were approximately $3.5 million, consistent with $3.5 million for the fourth quarter of 2015. Revenues reflect the loss of one of the Company's largest customers for the PLAC® ELISA Test, Atherotech, which filed for bankruptcy March 4, 2016, an increase in PLAC® ELISA Test volumes from other customers, and growth in PLAC® Activity Test volumes from new customers. Diadexus' second FDA-cleared test PLAC® Activity was launched actively in the fourth quarter of 2015.

Preliminary cash and cash equivalents at March 31, 2016 were approximately $6.3 million.

These preliminary results and balance are unaudited and may be subject to adjustment prior to Diadexus reporting financial results for the first quarter 2016, expected on or around April 28, 2016.

About Diadexus, Inc.
Diadexus, based in South San Francisco, California, is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. The Company pioneered the testing of Lp-PLA2, a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating its utility. Diadexus' products, The PLAC® Test ELISA Kit, first cleared by the FDA in 2003, and The PLAC® Test for Lp-PLA2 Activity, cleared in December 2014, are the only two FDA-cleared tests to measure Lp-PLA2.

The Company also has a pipeline of biomarkers for heart failure, proADM, proET-1 and proANP, each of which provide distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. To learn more about the PLAC® tests, please visit www.plactest.com, or visit the Company's website at www.diadexus.com.

Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, preliminary total revenues and cash and cash equivalents, statements related to our transition to a new business model and strategy and our ability to continue to execute our plans successfully, potential for revenue growth and expectations and guidance regarding our existing PLAC ELISA business, potential for pharmaceutical partner PLAC product collaborations, timing of regulatory submission and clinical and commercial need for our PLAC and ELISA tests. Forward-looking statements are based on current expectations and assumptions and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to us that could cause actual results to differ materially from those expressed in such forward-looking statements include the factors necessary to achieve our revenue and cash guidance; sales of our PLAC® products in the marketplace; our ability to maintain or grow revenues from existing and new customers, including hospitals, clinics and physician labs; viability of our leading customers; product pricing and demand with a concentrated customer base; the continued focus of regulatory agencies and payors on costs and our laboratory customer practices; our ability to continue to build our heart failure franchise; our ability to identify and build products with additional biomarkers; third party payors' acceptance of and reimbursement for the PLAC® tests; our ability to continue to manufacture the PLAC® tests to meet customer demand; the potential for success of and timing of when our development efforts may be completed; the adequacy of our intellectual property rights and our ability to maintain a proprietary position for our lead product; our limited revenue and cash resources; our significant corporate expenses, including real estate lease liabilities and expenses associated with being a public company; our ability to develop proADM for regulatory submission, and our ability to successfully integrate our new management leadership. Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found in our recent annual report on Form 10-K, and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth herein speaks only as of the date hereof, and except as required by law, we disclaim any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.

Contact:
Diadexus, Inc.
Leone Patterson
Chief Financial Officer
[phone]
Email Contact

Copyright © 2016 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

[Hawkeye_tt]

Did not like Top and Bottom Line in Q.

[subslover]

Revs not cutting it here!http://www.otcmarkets.com/stock/DDXS/news/Diadexus--Inc--Reports-Second-Quarter-2015-Financial-Results?id=112170&b=y

[subslover]

Names William Hammond As Vice President Of Sales [Market News Publishing (US)]

DIADEXUS INC

DIADEXUS INC ("DDXS-L") - Names William Hammond As Vice President Of Sales

Diadexus, Inc., a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that William Harrison Hammond (Hodi) has joined the Company as Vice President of Sales effective June 22, 2015. Mr. Hammond brings more than 30 years of experience in the medical diagnostics field, including 13 years in various senior and executive roles at Alere and 11 years at Abbott Diagnostics.

"Hodi brings extensive experience in sales and commercial strategy within the diagnostic market, with a deep understanding of the commercial channels," said Lori Rafield, Ph.D., chairman and chief executive officer for Diadexus. "His experience in developing relationships with accountable care organizations and integrated delivery networks will be invaluable as we execute our commercial strategy for our PLAC(r) ELISA and Activity portfolio of products and advance development of our initial heart failure diagnostic biomarker for measuring proADM."

"Diadexus is expanding into the larger hospital market for its PLAC(r) Activity Test while advancing proADM toward the market," said Mr. Hammond. "I look forward to working with the Diadexus team to maximize the commercial potential of the PLAC(r) franchise and prepare for the launch of our first heart failure diagnostic tests."

Most recently, Mr. Hammond was Vice President, Strategic Alliances at Sotera Wireless, an innovator in vital signs monitoring and remote patient surveillance, where he led the effort for contracting health systems, the federal government, and group purchasing organizations. Mr. Hammond previously served as Vice President, Accountable Care Group, at Alere, Inc., where he started and directed the company's efforts to sell all of Alere's diverse products including healthcare technology, POC diagnostics, and home health services designed to manage CHF patients to reduce unnecessary readmissions. Prior positions at Alere include Vice President Sales, Physicians Diagnostics Group, and Vice President, National Accounts. He came to Alere through their acquisition of Biosite where he played a pivotal role in sales and national accounts leadership in developing their POC business. Mr. Hammond previously held sales management positions at Roche Diagnostics, Precision Analytical Laboratories and Abbott Diagnostics. Mr. Hammond holds a B.A. in Economics from Bucknell University.

About Diadexus, Inc.

Diadexus, based in South San Francisco, California, is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. The Company pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating its utility. Diadexus' products, The PLAC(r) Test ELISA Kit, first cleared by the FDA in 2003, and The PLAC(r) Test for Lp-PLA2 Activity, cleared in December 2014, are the only two FDA-cleared tests to measure Lp-PLA2.

The Company also has a pipeline of biomarkers for heart failure, proADM, proET-1 and proANP, with each providing distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. For more information, please visit the Company's website at www.diadexus.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements," including statements regarding, among other things, the impact and the timing of the reverse stock split on the company's business, prospects and/or stock price. Forward-looking statements are based on current expectations and assumptions and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to us that could cause actual results to differ materially from those expressed in such forward-looking statements include the factors necessary to achieve our revenue guidance; sales of our PLAC(r) Test products in the marketplace; our ability to grow revenues from existing and new customers; product pricing and demand with a concentrated customer base; the continued focus of regulatory agencies and payors on costs and our laboratory customer practices; relationships with key customers; our ability to continue to build our heart failure franchise; our ability to identify and build products with additional biomarkers; third party payors' acceptance of and reimbursement for the PLAC(r) Tests; our ability to continue to manufacture the PLAC(r) Tests to meet customer demand; the potential for success of and timing of when our development efforts may be completed; the adequacy of our intellectual property rights and our ability to maintain a proprietary position for our lead product; our limited revenue and cash resources; our significant corporate expenses, including real estate lease liabilities and expenses associated with being a public company; our ability to develop proADM for regulatory submission, and our ability to successfully integrate our new management leadership. Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found in our most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth herein speaks only as of the date hereof, and except as required by law, we disclaim any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.

Investor Contact: Melissa Forst Argot Partners 212-600-1902

______________________________________

_______________________________________________

OTCBB closing price for DDXS-L Date: 2015/06/30 Closing Price: 0.34

____________________________________________________________
(c)2015 Market News Publishing Inc. All rights reserved.
Toronto:[phone] Vancouver:[phone] Fax:[phone]
© (c) 2015 Market News Publishing Inc.
< Back

click here
Our Marketplaces



Market Info
Contact Us
Advertising
Market Hours/Holidays
Corporate Info
About Us
Investor Relations
Press Center
Careers
Sign up for the Newsletter

View Previous Newsletters

Follow Us:
© 2015 OTC Markets Group Inc.Terms of ServiceLinking TermsTrademarksPrivacy StatementRisk WarningSite MapGive FeedbackSupported Browsers? Jump to Top

OTC Link® ATS provided by OTC Link LLC, member FINRA / SIPC, a wholly owned subsidiary of OTC Markets Group Inc.
OTCQX, OTCQB and OTC Pink marketplaces designated by OTC Markets Group.

AdTech Ad

[Hawkeye_tt]

No help so far.......
Need some Real news now.

[Renee]

DDXS one for 15 reverse split:

http://investorshub.advfn.com/boards/manage_msg.asp?message_id=115056493

[subslover]

1st QT out here http://www.otcmarkets.com/stock/DDXS/news/Diadexus--Inc--Reports-First-Quarter-2015-Financial-Results?id=104354&b=y

[subslover]

$156k dollar bid @ .36 so something about to happen IMHO.

[subslover]

This must be why the buying volume exploded at the close.

http://www.otcmarkets.com/stock/DDXS/news

[subslover]

Some very nice block buys at the end of the trading session. Maybe,just maybe it will continue upon the open.

[Hawkeye_tt]

Would have liked to see a price Target from them.

[Pennybuster]

Very Nice Subs.. Thank You!

[subslover]

This came out yesterday and its very promising. http://www.wkrb13.com/markets/496786/diadexus-upgraded-to-buy-at-ladenburg-thalmann-ddxs/

[Hawkeye_tt]

As I was hoping After Dec...
GLA.

Hawk

[Pennybuster]

$DDXS Ready 2 Roll IMHO!! GLTU :)

[subslover]

DDXS is on fire! Heavy buying all week to close at .51 :)

[subslover]

Very strong day up 27% with healthy volume & deep bid gaps all afternoon.

[Hawkeye_tt]

JMO...this is a buy low/now and hold through Q1&2 next yr.
Have a strong position now and will patient through then.
GL

[Tdash]

Seems like a good company but the trading sucks.. I know many new investors lost money here

[Tdash]

ARCA is back up.. Im done here for now. Good luck.. you might wanna try getting Level2 it helps. Later

[Tdash]

Everyone is buying.. I can see that from Level2. But the bid is being held back for some reason(ARCA) like i said before. Hopefully it moves before people get tired of buying and start selling.

[north40000]

In light of FDA approval, why not buy at the ASK?

[Tdash]

Thats why u don't understand what I'm saying. DDXS had so many buys at .40 but never went up because ARCA was holding shares.. ARCA has now moved to .425 and this will eventually be stuck there. Once ARCA has no more shares this will run.. You will have to get Level 2 to further understand

[north40000]

No...If you mean level2 trading.

[Tdash]

Do you have L2??

[north40000]

How must ARCA move. What does it have to do with DDXS P/S?

[Tdash]

ARCA is holding this one back big time. This would have been .50+ already.. most likely will move higher tomorrow or whenever ARCA has moved

[subslover]

Here ya go. http://seekingalpha.com/news/2179345-fda-clears-diadexus-chd-screening-test

[Planopenny]

yep

[Hawkeye_tt]

Someone just Loadd the Boat....JMO

GL in 2015 here...

[subslover]

And it ain't good http://tickerreport.com/banking-finance/339084/diadexus-ddxs-announces-quarterly-earnings-misses-estimates-by-0-02-eps/

[Hawkeye_tt]

Q report today.
Going to dial in if time.
GLA.........

Hawk

[subslover]

Insider buys 160k shares @ .50 http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10248499

[subslover]

News on new 15 mil dollar financing

http://online.wsj.com/article/PR-CO-20140818-904366.html

[subslover]

Downgrade News http://tickerreport.com/banking-finance/260457/diadexus-pt-lowered-to-1-75-ddxs/

[subslover]

NEWS. http://www.marketwatch.com/story/diadexus-announces-fda-acceptance-for-review-of-510k-submission-for-plac-test-for-lp-pla2-activity-2014-07-17

[subslover]

New President to begin on Aug 4th News link below

http://www.marketwatch.com/story/diadexus-announces-leadership-changes-to-drive-and-support-future-growth-potential-2014-06-25

[Planopenny]

hey dipshit...u buy back in yet ;) My .65's are niiiiice right now